Published in J Infect Dis on November 01, 1977
Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody. J Clin Microbiol (1979) 1.97
Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine (2008) 1.54
Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond) (1981) 1.51
Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. Thorax (1989) 1.49
Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol (1996) 1.36
Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res (2008) 1.31
Time to peak serum antibody response to influenza vaccine. Clin Diagn Lab Immunol (1995) 1.25
Time to peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol (1996) 1.22
Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 1.22
Influenza vaccines. Vaccine (2009) 1.17
Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine (2008) 1.16
Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ (1991) 1.16
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol (1997) 0.91
A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets. Vaccine (2014) 0.89
Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children. J Clin Pathol (1979) 0.89
Comparison of new triton X-100- and tween-ether-treated split-treated vaccines in children. J Clin Microbiol (1981) 0.87
Influenza, immune system, and pregnancy. Reprod Sci (2014) 0.86
Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS PharmSciTech (2013) 0.78
Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. Int J Chron Obstruct Pulmon Dis (2007) 0.77
Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv (2014) 0.77
Sequential infection or immunization of ferrets with a series of influenza A (H3N2) strains (report to the Medical Research Council's Sub-Committee on influenza Vaccines (CDVIP/IV)). Epidemiol Infect (1987) 0.75
Recent developments in seasonal and pandemic influenza vaccines. Influenza Other Respir Viruses (2008) 0.75
Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. Pediatr Infect Dis J (2014) 0.75
Investigation into alternative testing methodologies for characterization of influenza virus vaccine. Hum Vaccin Immunother (2015) 0.75
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis (1997) 5.13
Early clinical and laboratory indicators of acute dengue illness. J Infect Dis (1997) 5.00
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science (1988) 3.44
Immunopathogenesis of Dengue hemorrhagic fever. Virology (1999) 3.16
Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis (1999) 2.96
Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr (1977) 2.66
Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol (1999) 2.54
Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol (1990) 2.47
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest (1991) 2.37
Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol (1996) 2.35
Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol (1981) 2.19
HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens (2002) 2.18
Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol (1998) 2.18
Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol (1998) 2.10
Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol (1981) 2.04
High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis (1999) 2.02
Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest (1989) 2.01
Hemagglutinin-specific cytotoxic T-cell response during influenza infection. J Exp Med (1977) 1.97
Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody. J Clin Microbiol (1979) 1.97
Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol (2001) 1.92
Cytotoxic T lymphocyte response to murine cytomegalovirus infection. Nature (1978) 1.89
Influenza virus infection in nude mice. J Infect Dis (1976) 1.85
Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis (1999) 1.82
An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol (1991) 1.80
Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol (1999) 1.79
Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis (1983) 1.79
Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers. Am J Trop Med Hyg (1997) 1.75
Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol (1988) 1.71
Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med (1989) 1.68
Host defense mechanisms against Herpes simplex virus. I. Control of infection in vitro by senstized spleen cells and antibody. Infect Immun (1973) 1.67
Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol (1984) 1.66
Immune interferon produced to high levels by antigenic stimulation of human lymphocytes with influenza virus. J Exp Med (1981) 1.64
Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis (1983) 1.64
A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6. J Virol (1992) 1.63
Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg (1998) 1.63
Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol Suppl (1994) 1.61
The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol (1978) 1.60
Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand (1980) 1.59
Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis (1994) 1.56
High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg (1993) 1.56
Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol (1989) 1.55
Specificity studies on cytotoxic thymus-derived lymphocytes reactive with influenza virus-infected cells: evidence for dual recognition of H-2 and viral hemagglutinin antigens. Proc Natl Acad Sci U S A (1977) 1.53
Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol (1991) 1.52
Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. Am J Dis Child (1979) 1.51
Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol (1991) 1.50
Impaired T cell proliferation in acute dengue infection. J Immunol (1999) 1.46
Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes. J Virol (1992) 1.46
Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J Infect Dis (1977) 1.45
Fatal measles infection in marmosets pathogenesis and prophylaxis. Infect Immun (1980) 1.43
Host defense mechanisms against herpes simplex virus. II. Protection conferred by sensitized spleen cells. J Infect Dis (1973) 1.39
Influenza virus hemagglutinin-specific cytotoxic T cell response induced by polypeptide produced in Escherichia coli. J Exp Med (1985) 1.37
Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest (1996) 1.35
Infertility in male patients with cystic fibrosis. Pediatrics (1968) 1.34
Clinical studies with experimental live rubella virus vaccine (strain HPV-77). Evaluation of vaccine-induced immunity. Am J Dis Child (1968) 1.34
Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol (1995) 1.32
Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol (1998) 1.31
Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol (1999) 1.29
HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet (1981) 1.28
Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones. J Virol (1996) 1.28
Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections. Arch Virol (1990) 1.27
Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein. Proc Natl Acad Sci U S A (1991) 1.26
Sensitive neutralization test for virus antibody. 1. Mumps antibody. Arch Virol (1978) 1.25
Time to peak serum antibody response to influenza vaccine. Clin Diagn Lab Immunol (1995) 1.25
Evidence that cytotoxic T cells are part of the host's response to influenza pneumonia. J Exp Med (1978) 1.25
Latent cytomegalovirus infection of BALB/c mouse spleens detected by an explant culture technique. J Gen Virol (1979) 1.24
Induction of interferon alpha and gamma from human lymphocytes by dengue virus-infected cells. J Gen Virol (1986) 1.24
High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis (1999) 1.24
Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J Med Virol (2001) 1.24
Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans. J Virol (1993) 1.23
Polymicrobic bacteriuria: significant association with bacteremia. J Clin Microbiol (1976) 1.23
Deaths from nosocomial infections: experience in a university hospital and a community hospital. Am J Med (1980) 1.22
Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol (1996) 1.22
Pneumothorax as a complication of cystic fibrosis. Report of twenty cases. Am J Dis Child (1968) 1.21
Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet (1981) 1.21
Dengue virus-specific murine T-lymphocyte proliferation: serotype specificity and response to recombinant viral proteins. J Virol (1989) 1.20
Blood and liver concentrations of vitamins A and E in children with cystic fibrosis of the pancreas. Pediatr Res (1972) 1.20
Influenza A viruses of the H2N2 subtype are lymphocyte mitogens. Nature (1978) 1.20
Host defense mechanisms against influenza virus: interaction of influenza virus with murine macrophages in vitro. Infect Immun (1978) 1.19
Hepatitis B immunization strategies: expanding the target. Ann Intern Med (1993) 1.18
Diagnostic importance of an increased serum anion gap. N Engl J Med (1980) 1.18
Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. J Infect Dis (1977) 1.16
Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF. Arch Virol (1992) 1.16
Cooperative study comparing three methods of performing sweat tests to diagnose cystic fibrosis. Pediatrics (1980) 1.16
Human immune responses to dengue viruses. Southeast Asian J Trop Med Public Health (1990) 1.15
HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. J Immunol (1988) 1.14
Human interferon alpha and gamma production by lymphocytes during the generation of influenza virus-specific cytotoxic T lymphocytes. J Gen Virol (1986) 1.14
Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol (1992) 1.13
Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J Infect Dis (1994) 1.13
Influenza immunization policies and practices in Japan. J Infect Dis (1980) 1.12
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol (1999) 1.11
The elimination of herpes simplex plaques by antibody and the emergence of resistant strains. J Immunol (1977) 1.11
Comparative evaluation of different types of blood culture media for isolation of aerobes. J Clin Microbiol (1977) 1.10
Subacute sclerosing panencephalitis: experimental infection in primates. Science (1977) 1.10
Review of existing vaccines for influenza. Am J Clin Pathol (1978) 1.09
Ultrastructural studies of the envelopment and release of guinea pig herpes-like virus in cultured cells. Virology (1973) 1.09
Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis (1997) 1.09